Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Sponsor: Remix Therapeutics
This PHASE1/PHASE2 trial investigates Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma and is currently actively recruiting participants. Remix Therapeutics leads this study, which shows 11 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1 → PHASE1/PHASE2
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Remix Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .